ANAPTYSBIO director exercises 6,030 RSUs into shares

ANAPTYSBIO director John A. Orwin exercised restricted stock units into common shares.

Rhea-AI Filing Summary

ANAPTYSBIO director John A. Orwin exercised restricted stock units into common shares. On June 15, 2026, he converted 6,030 restricted stock units into 6,030 shares of common stock at no cash cost, increasing his directly held stake to 16,695 shares.

Each RSU represents a right to receive one share of common stock upon settlement. The RSU award was structured to vest 100% on June 15, 2026, contingent on Mr. Orwin’s continued service to the company through that date. The filing reports no share sales, tax withholding, or gifts in connection with this transaction.

Insider Trade Summary

6,030 shares exercised/converted

Exercise 2 txns

Insider Orwin John A

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	$0.00
Exercise	Common Stock	6,030	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 16,695 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs exercised: 6,030 units Common shares acquired: 6,030 shares Shares held after transaction: 16,695 shares +3 more

6 metrics

RSUs exercised 6,030 units Restricted stock units converted to common stock on June 15, 2026

Common shares acquired 6,030 shares Shares received upon RSU settlement at no cash cost

Shares held after transaction 16,695 shares Direct common stock ownership following RSU conversion

Exercise price per RSU $0.00 per share RSUs settle for no consideration into common stock

Transaction code M Exercise or conversion of derivative security on Form 4

Exercise transactions 1 transaction, 6,030 shares Aggregate derivative exercise activity in this Form 4

Key Terms

Restricted Stock Unit, contingent right, vests, derivative security, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock"

vests financial

"The RSUs vests as to 100% of the total RSUs on June 15, 2026"

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANAPTYSBIO (ANAB) report for John A. Orwin?

ANAPTYSBIO reported that director John A. Orwin exercised 6,030 restricted stock units into 6,030 common shares. This non-cash transaction reflects settlement of vested equity compensation rather than an open-market purchase or sale, and no shares were sold or gifted in this filing.

How many ANAPTYSBIO (ANAB) shares does John A. Orwin hold after this Form 4?

After the June 15, 2026 RSU settlement, John A. Orwin directly holds 16,695 shares of ANAPTYSBIO common stock. The filing shows no remaining derivative position for these RSUs, indicating the entire 6,030-unit award was converted into common shares on that date.

Were any ANAPTYSBIO (ANAB) shares sold or withheld for taxes in this Form 4?

No. The Form 4 shows only an exercise of restricted stock units into 6,030 common shares and no dispositions. There are no reported sales, tax-withholding share reductions, gifts, or restructurings associated with this RSU vesting and conversion event.

What are ANAPTYSBIO (ANAB) restricted stock units as described in this filing?

Each ANAPTYSBIO restricted stock unit represents a contingent right to receive one share of common stock upon settlement for no consideration. The award in this filing vested 100% on June 15, 2026, conditioned on the reporting person’s continued service through that vesting date.

When did John A. Orwin’s ANAPTYSBIO (ANAB) RSUs vest and settle?

The restricted stock units vested and settled on June 15, 2026. On that date, 6,030 RSUs converted into 6,030 shares of ANAPTYSBIO common stock, assuming the director satisfied the service requirement through the full vesting date specified in the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Orwin John A

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		6,030	A	$0(1)	16,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/15/2026		M			6,030	(2)	(2)	Common Stock	6,030	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Christopher Murphy, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)